TrialDiabetologia2025

Sex differences in response to the endothelin receptor antagonist atrasentan in individuals with type 2 diabetes and chronic kidney disease: a post hoc analysis of the SONAR trial.

J David Smeijer et al.PubMed ↗Publisher ↗

No numbers read from the abstract.